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Infrapopliteal Disease
Digging Deep to Understand the Impact of a Negative Trial*John R. Laird, MD,y Ehrin J. Armstrong, MDzO ver the past decade, drug-coated balloons(DCBs) have emerged as an effective treat-ment for atherosclerosis in multiple
vascular beds. Initial attempts to deliver antireste-
notic agents locally without a stent scaffold included
use of infusion balloons, injection into the arterial
wall, and admixing drug with contrast media (1).
Each of these approaches suffered from technical lim-
itations or unpredictable systemic drug dosing. The
insight that paclitaxel can be coated on an angioplasty
balloon provided an important breakthrough in local
drug delivery (2). DCBs rely on 3 mechanisms related
to paclitaxel’s lipophilicity. First, crystalline pacli-
taxel can be combined with an excipient, such as
contrast media, to coat an angioplasty balloon. Sec-
ond, paclitaxel stays largely bound to the excipient
and balloon during advancement to the target vessel.
Third, a brief (1 to 3 min) inﬂation of the balloon at the
target vessel is sufﬁcient for local delivery of a thera-
peutic dose of paclitaxel, which then resides in tissues
for months (3,4). All currently available paclitaxel-
coated balloons rely on a speciﬁc excipient (e.g.,
iopromide, shellac, urea, butyryl trihexyl citrate) and
paclitaxel at doses ranging from 2.0 to 3.5 mg/mm2.
DCBs were shown to be effective in treatment
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treat in-stent restenosis with efﬁcacy similar to that
of a paclitaxel-eluting stent and superior to standard
balloon angioplasty (5,6). Coronary DCBs are also
useful for the treatment of lesions in small coronary
arteries and bifurcation lesions (7). In the peripheral
arteries, DCBs improve the rates of primary patency
for de novo femoropopliteal lesions compared to
percutaneous transluminal angioplasty (PTA) (8–11),
and may be particularly beneﬁcial in the treatment
of femoropopliteal in-stent restenosis (12).
These positive results have led to speculation that
DCBs could also be efﬁcacious in the treatment of
infrapopliteal occlusive disease in patients presenting
with critical limb ischemia (CLI). While PTA has his-
torically provided acceptable angiographic results
and reasonable limb salvage rates when used to treat
infrapopliteal disease, it is plagued by high rates of
restenosis and need for repeat interventions. Schmidt
et al. demonstrated an angiographic restenosis rate of
68.8% at 3 months following PTA of long infrapopli-
teal lesions and a need for reintervention in 50% of
cases (13). These same investigators later showed
signiﬁcantly better outcomes when treating a similar
cohort of patients with DCBs. Angiographic restenosis
was only 27.4%, with a signiﬁcant reduction to 17.3%
in the need for target lesion revascularization (TLR)
(14). Liistro et al. (15) subsequently performed a
single-center randomized trial of DCB versus PTA in
diabetic patients with CLI, which demonstrated a
signiﬁcant reduction in 12-month angiographic
restenosis (27% vs. 74%) and need for reintervention
(18% vs. 43%).
These encouraging, but preliminary, ﬁndings led to
the development and conduct of a larger, multi-
center, randomized clinical trial. In this issue of the
Journal, Zeller et al. (16) report the results of the
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1578IN.PACT DEEP trial (Study of IN.PACT Amphirion
Drug Eluting Balloon vs. Standard PTA for the Treat-
ment of Below the Knee Critical Limb Ischemia). ThisSEE PAGE 1568well-designed, industry-sponsored trial included an
independent data safety monitoring board and clin-
ical events committee, as well as independent, blin-
ded core laboratories for angiography, duplex
ultrasound, and wound assessment. A total of 358
patients were randomized (2:1) between DCB and
PTA. The 2 coprimary efﬁcacy endpoints of the trial
were clinically driven TLR (CD-TLR) and angiographic
late lumen loss. The primary safety endpoint through
6 months was a composite of all-cause mortality,
major amputation, and CD-TLR.
Despite use of the same DCB (IN.PACT Amphirion,
Medtronic, Santa Rosa, California) that was evaluated
in the aforementioned single-center retrospective
and prospective studies, the IN.PACT DEEP trial in-
vestigators were unable to demonstrate any beneﬁt of
DCB in this randomized trial. There were no signiﬁ-
cant differences with regard to CD-TLR or angio-
graphic late lumen loss. While the study met its
noninferiority hypothesis with regard to the primary
safety endpoint, there were more complications in
the DCB arm of the trial and a trend toward more
major amputations (8.8% vs. 3.6%; p ¼ 0.080) and
lower amputation-free survival (81.1% vs. 89.2%;
p ¼ 0.057).
How do we explain the disparate results between
the IN.PACT DEEP trial and previous investigations
of DCB in infrapopliteal and femoropopliteal vascular
territories? Was there a problem with the trial design?
Was there a problem with this particular DCB plat-
form? Or was this just 1 more example of a well-done
randomized trial failing to reproduce the results from
smaller or nonrandomized studies? It is difﬁcult to be
too critical of this well-conducted clinical trial.
However, as the authors point out, the trial was not
powered to demonstrate differences in major ampu-
tation rates, and there was not a predeﬁned and
consistent approach to wound care. The differences
with regard to safety between DCB and PTA areperhaps most easily addressed. While the amputation
rate was 2.4-fold higher in the DCB arm of the trial,
the 3.6% major amputation rate in the PTA arm is
remarkably low and certainly an outlier compared to
major amputation rates from previous studies of PTA
and other endovascular therapies for CLI (17–19).
These outstanding PTA outcomes were achieved
despite inclusion of a high percentage of Rutherford
class 5 patients and likely reﬂect good PTA results
followed by excellent wound care.
There are important differences between the
IN.PACT Amphirion DCB platform and other DCBs
studied in the SFA. The balloon is constructed of
different material and the coating process is entirely
different. The IN.PACT Amphirion balloon is manu-
ally coated after it is folded, resulting in nonuniform
paclitaxel distribution on the balloon. The bulk of the
adherent drug is in an exposed position (not pro-
tected by balloon folds) and subject to loss during
advancement through the sheath and tracking to the
lesion. The lack of an observed treatment effect in the
current study might well be explained by an insufﬁ-
cient paclitaxel dose delivered into the vessel wall.
These limitations of the balloon coating process,
together with concerns regarding the trend toward a
higher amputation rate with DCB, led to Medtronic’s
withdrawal of the IN.PACT DCB from the market.
Where do we go from here? On the basis of the
IN.PACT DEEP trial’s results, it is premature to
conclude that there is no role for DCBs in infrapopli-
teal disease in patients with CLI. While the results of
PTA in this trial were remarkably good, there is still a
need for a therapy that provides more durable
patency in this vascular bed and reduces the need for
repeat interventions. DCBs that can deliver thera-
peutic levels of paclitaxel into the vessel wall may
still play a role. We await the results of additional
trials, including the results of an ongoing randomized
trial in the United States.
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